CN102240399B - 鳜传染性脾肾坏死病毒(isknv)orf093蛋白的应用 - Google Patents
鳜传染性脾肾坏死病毒(isknv)orf093蛋白的应用 Download PDFInfo
- Publication number
- CN102240399B CN102240399B CN 201110191339 CN201110191339A CN102240399B CN 102240399 B CN102240399 B CN 102240399B CN 201110191339 CN201110191339 CN 201110191339 CN 201110191339 A CN201110191339 A CN 201110191339A CN 102240399 B CN102240399 B CN 102240399B
- Authority
- CN
- China
- Prior art keywords
- isknv
- orf093
- protein
- siniperca chuatsi
- necrosis virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241001051238 Infectious spleen and kidney necrosis virus Species 0.000 title claims abstract description 70
- -1 F093 Species 0.000 title claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 title abstract description 20
- 241000264847 Siniperca chuatsi Species 0.000 title abstract description 18
- 102000004169 proteins and genes Human genes 0.000 title abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 229960005486 vaccine Drugs 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 8
- 241000404975 Synchiropus splendidus Species 0.000 claims description 34
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 8
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 241000251468 Actinopterygii Species 0.000 description 6
- 101710121996 Hexon protein p72 Proteins 0.000 description 6
- 101710125418 Major capsid protein Proteins 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000385 dialysis solution Substances 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000004958 brain cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 241000701372 Iridovirus Species 0.000 description 3
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229940023146 nucleic acid vaccine Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009465 prokaryotic expression Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000004153 renaturation Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 108010073969 valyllysine Proteins 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000920592 Red seabream iridovirus Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000004459 forage Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 108010053725 prolylvaline Proteins 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- WXPZDDCNKXMOMC-AVGNSLFASA-N (2s)-1-[(2s)-2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@H](C(O)=O)CCC1 WXPZDDCNKXMOMC-AVGNSLFASA-N 0.000 description 1
- 241001519451 Abramis brama Species 0.000 description 1
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
- BTBUEVAGZCKULD-XPUUQOCRSA-N Ala-Gly-His Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BTBUEVAGZCKULD-XPUUQOCRSA-N 0.000 description 1
- MDNAVFBZPROEHO-DCAQKATOSA-N Ala-Lys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MDNAVFBZPROEHO-DCAQKATOSA-N 0.000 description 1
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 1
- IHRGVZXPTIQNIP-NAKRPEOUSA-N Ala-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)N IHRGVZXPTIQNIP-NAKRPEOUSA-N 0.000 description 1
- HCBKAOZYACJUEF-XQXXSGGOSA-N Ala-Thr-Gln Chemical compound N[C@@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O HCBKAOZYACJUEF-XQXXSGGOSA-N 0.000 description 1
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 1
- JPOQZCHGOTWRTM-FQPOAREZSA-N Ala-Tyr-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPOQZCHGOTWRTM-FQPOAREZSA-N 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- OTOXOKCIIQLMFH-KZVJFYERSA-N Arg-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N OTOXOKCIIQLMFH-KZVJFYERSA-N 0.000 description 1
- DNBMCNQKNOKOSD-DCAQKATOSA-N Arg-Pro-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O DNBMCNQKNOKOSD-DCAQKATOSA-N 0.000 description 1
- AWMAZIIEFPFHCP-RCWTZXSCSA-N Arg-Pro-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O AWMAZIIEFPFHCP-RCWTZXSCSA-N 0.000 description 1
- VUGWHBXPMAHEGZ-SRVKXCTJSA-N Arg-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N VUGWHBXPMAHEGZ-SRVKXCTJSA-N 0.000 description 1
- XEOXPCNONWHHSW-AVGNSLFASA-N Arg-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N XEOXPCNONWHHSW-AVGNSLFASA-N 0.000 description 1
- LZLCLRQMUQWUHJ-GUBZILKMSA-N Asn-Lys-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N LZLCLRQMUQWUHJ-GUBZILKMSA-N 0.000 description 1
- AMGQTNHANMRPOE-LKXGYXEUSA-N Asn-Thr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O AMGQTNHANMRPOE-LKXGYXEUSA-N 0.000 description 1
- BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 1
- SLHOOKXYTYAJGQ-XVYDVKMFSA-N Asp-Ala-His Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 SLHOOKXYTYAJGQ-XVYDVKMFSA-N 0.000 description 1
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 1
- YRBGRUOSJROZEI-NHCYSSNCSA-N Asp-His-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(O)=O YRBGRUOSJROZEI-NHCYSSNCSA-N 0.000 description 1
- QOCFFCUFZGDHTP-NUMRIWBASA-N Asp-Thr-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOCFFCUFZGDHTP-NUMRIWBASA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000703788 Cirrhinus molitorella Species 0.000 description 1
- 206010010254 Concussion Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IVCOYUURLWQDJQ-LPEHRKFASA-N Gln-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O IVCOYUURLWQDJQ-LPEHRKFASA-N 0.000 description 1
- MLSKFHLRFVGNLL-WDCWCFNPSA-N Gln-Leu-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MLSKFHLRFVGNLL-WDCWCFNPSA-N 0.000 description 1
- VNTGPISAOMAXRK-CIUDSAMLSA-N Gln-Pro-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O VNTGPISAOMAXRK-CIUDSAMLSA-N 0.000 description 1
- MXOODARRORARSU-ACZMJKKPSA-N Glu-Ala-Ser Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N MXOODARRORARSU-ACZMJKKPSA-N 0.000 description 1
- UGSVSNXPJJDJKL-SDDRHHMPSA-N Glu-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N UGSVSNXPJJDJKL-SDDRHHMPSA-N 0.000 description 1
- UMZHHILWZBFPGL-LOKLDPHHSA-N Glu-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O UMZHHILWZBFPGL-LOKLDPHHSA-N 0.000 description 1
- XUDLUKYPXQDCRX-BQBZGAKWSA-N Gly-Arg-Asn Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O XUDLUKYPXQDCRX-BQBZGAKWSA-N 0.000 description 1
- DTPOVRRYXPJJAZ-FJXKBIBVSA-N Gly-Arg-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N DTPOVRRYXPJJAZ-FJXKBIBVSA-N 0.000 description 1
- OCDLPQDYTJPWNG-YUMQZZPRSA-N Gly-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN OCDLPQDYTJPWNG-YUMQZZPRSA-N 0.000 description 1
- GNPVTZJUUBPZKW-WDSKDSINSA-N Gly-Gln-Ser Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GNPVTZJUUBPZKW-WDSKDSINSA-N 0.000 description 1
- LPCKHUXOGVNZRS-YUMQZZPRSA-N Gly-His-Ser Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O LPCKHUXOGVNZRS-YUMQZZPRSA-N 0.000 description 1
- UESJMAMHDLEHGM-NHCYSSNCSA-N Gly-Ile-Leu Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O UESJMAMHDLEHGM-NHCYSSNCSA-N 0.000 description 1
- BHPQOIPBLYJNAW-NGZCFLSTSA-N Gly-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN BHPQOIPBLYJNAW-NGZCFLSTSA-N 0.000 description 1
- UWQDKRIZSROAKS-FJXKBIBVSA-N Gly-Met-Thr Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWQDKRIZSROAKS-FJXKBIBVSA-N 0.000 description 1
- YOBGUCWZPXJHTN-BQBZGAKWSA-N Gly-Ser-Arg Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YOBGUCWZPXJHTN-BQBZGAKWSA-N 0.000 description 1
- KSOBNUBCYHGUKH-UWVGGRQHSA-N Gly-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN KSOBNUBCYHGUKH-UWVGGRQHSA-N 0.000 description 1
- MBSSHYPAEHPSGY-LSJOCFKGSA-N His-Ala-Met Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O MBSSHYPAEHPSGY-LSJOCFKGSA-N 0.000 description 1
- ZPVJJPAIUZLSNE-DCAQKATOSA-N His-Arg-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O ZPVJJPAIUZLSNE-DCAQKATOSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- IGJWJGIHUFQANP-LAEOZQHASA-N Ile-Gly-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N IGJWJGIHUFQANP-LAEOZQHASA-N 0.000 description 1
- KIAOPHMUNPPGEN-PEXQALLHSA-N Ile-Gly-His Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KIAOPHMUNPPGEN-PEXQALLHSA-N 0.000 description 1
- AREBLHSMLMRICD-PYJNHQTQSA-N Ile-His-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N AREBLHSMLMRICD-PYJNHQTQSA-N 0.000 description 1
- ANTFEOSJMAUGIB-KNZXXDILSA-N Ile-Thr-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N ANTFEOSJMAUGIB-KNZXXDILSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 description 1
- LAPSXOAUPNOINL-YUMQZZPRSA-N Leu-Gly-Asp Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O LAPSXOAUPNOINL-YUMQZZPRSA-N 0.000 description 1
- YRRCOJOXAJNSAX-IHRRRGAJSA-N Leu-Pro-Lys Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N YRRCOJOXAJNSAX-IHRRRGAJSA-N 0.000 description 1
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
- 241001417534 Lutjanidae Species 0.000 description 1
- FUKDBQGFSJUXGX-RWMBFGLXSA-N Lys-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)C(=O)O FUKDBQGFSJUXGX-RWMBFGLXSA-N 0.000 description 1
- ALEVUGKHINJNIF-QEJZJMRPSA-N Lys-Phe-Ala Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 ALEVUGKHINJNIF-QEJZJMRPSA-N 0.000 description 1
- RMOKGALPSPOYKE-KATARQTJSA-N Lys-Thr-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMOKGALPSPOYKE-KATARQTJSA-N 0.000 description 1
- MUYQDMBLDFEVRJ-LSJOCFKGSA-N Met-Ala-His Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 MUYQDMBLDFEVRJ-LSJOCFKGSA-N 0.000 description 1
- SCKPOOMCTFEVTN-QTKMDUPCSA-N Met-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCSC)N)O SCKPOOMCTFEVTN-QTKMDUPCSA-N 0.000 description 1
- FWAHLGXNBLWIKB-NAKRPEOUSA-N Met-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCSC FWAHLGXNBLWIKB-NAKRPEOUSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000353172 Oplegnathus fasciatus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- MQWISMJKHOUEMW-ULQDDVLXSA-N Phe-Arg-His Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 MQWISMJKHOUEMW-ULQDDVLXSA-N 0.000 description 1
- FIRWJEJVFFGXSH-RYUDHWBXSA-N Phe-Glu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FIRWJEJVFFGXSH-RYUDHWBXSA-N 0.000 description 1
- WEDZFLRYSIDIRX-IHRRRGAJSA-N Phe-Ser-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 WEDZFLRYSIDIRX-IHRRRGAJSA-N 0.000 description 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
- MLQVJYMFASXBGZ-IHRRRGAJSA-N Pro-Asn-Tyr Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O MLQVJYMFASXBGZ-IHRRRGAJSA-N 0.000 description 1
- HAEGAELAYWSUNC-WPRPVWTQSA-N Pro-Gly-Val Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAEGAELAYWSUNC-WPRPVWTQSA-N 0.000 description 1
- LPGSNRSLPHRNBW-AVGNSLFASA-N Pro-His-Val Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C([O-])=O)NC(=O)[C@H]1[NH2+]CCC1)C1=CN=CN1 LPGSNRSLPHRNBW-AVGNSLFASA-N 0.000 description 1
- WIPAMEKBSHNFQE-IUCAKERBSA-N Pro-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@@H]1CCCN1 WIPAMEKBSHNFQE-IUCAKERBSA-N 0.000 description 1
- SPLBRAKYXGOFSO-UNQGMJICSA-N Pro-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2)O SPLBRAKYXGOFSO-UNQGMJICSA-N 0.000 description 1
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 1
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- OBXVZEAMXFSGPU-FXQIFTODSA-N Ser-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)CN=C(N)N OBXVZEAMXFSGPU-FXQIFTODSA-N 0.000 description 1
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- SYCFMSYTIFXWAJ-DCAQKATOSA-N Ser-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CO)N SYCFMSYTIFXWAJ-DCAQKATOSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 1
- CAGTXGDOIFXLPC-KZVJFYERSA-N Thr-Arg-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N CAGTXGDOIFXLPC-KZVJFYERSA-N 0.000 description 1
- VGYBYGQXZJDZJU-XQXXSGGOSA-N Thr-Glu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VGYBYGQXZJDZJU-XQXXSGGOSA-N 0.000 description 1
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 1
- RRRRCRYTLZVCEN-HJGDQZAQSA-N Thr-Leu-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O RRRRCRYTLZVCEN-HJGDQZAQSA-N 0.000 description 1
- SIEZEMFJLYRUMK-YTWAJWBKSA-N Thr-Met-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N)O SIEZEMFJLYRUMK-YTWAJWBKSA-N 0.000 description 1
- BCYUHPXBHCUYBA-CUJWVEQBSA-N Thr-Ser-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O BCYUHPXBHCUYBA-CUJWVEQBSA-N 0.000 description 1
- NQQMWWVVGIXUOX-SVSWQMSJSA-N Thr-Ser-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NQQMWWVVGIXUOX-SVSWQMSJSA-N 0.000 description 1
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- NSGZILIDHCIZAM-KKUMJFAQSA-N Tyr-Leu-Ser Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N NSGZILIDHCIZAM-KKUMJFAQSA-N 0.000 description 1
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 1
- XLDYBRXERHITNH-QSFUFRPTSA-N Val-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)C(C)C XLDYBRXERHITNH-QSFUFRPTSA-N 0.000 description 1
- ZSZFTYVFQLUWBF-QXEWZRGKSA-N Val-Asp-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N ZSZFTYVFQLUWBF-QXEWZRGKSA-N 0.000 description 1
- KZKMBGXCNLPYKD-YEPSODPASA-N Val-Gly-Thr Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O KZKMBGXCNLPYKD-YEPSODPASA-N 0.000 description 1
- PTFPUAXGIKTVNN-ONGXEEELSA-N Val-His-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)NCC(=O)O)N PTFPUAXGIKTVNN-ONGXEEELSA-N 0.000 description 1
- OVBMCNDKCWAXMZ-NAKRPEOUSA-N Val-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N OVBMCNDKCWAXMZ-NAKRPEOUSA-N 0.000 description 1
- WSUWDIVCPOJFCX-TUAOUCFPSA-N Val-Met-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N WSUWDIVCPOJFCX-TUAOUCFPSA-N 0.000 description 1
- RYQUMYBMOJYYDK-NHCYSSNCSA-N Val-Pro-Glu Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RYQUMYBMOJYYDK-NHCYSSNCSA-N 0.000 description 1
- AJNUKMZFHXUBMK-GUBZILKMSA-N Val-Ser-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N AJNUKMZFHXUBMK-GUBZILKMSA-N 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001759 immunoprophylactic effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108700004896 tripeptide FEG Proteins 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
本发明公开了鳜传染性脾肾坏死病毒(ISKNV)ORF093蛋白在制备预防鳜传染性脾肾坏死病毒病疫苗或药物中的应用。本发明的鳜ISKNVORF093蛋白对鳜虹彩病毒病有较好的免疫预防作用,保护率超过45%,可以开发成为抗鳜鱼传染性脾肾坏死病毒病新疫苗或新药物。
Description
技术领域
本发明属于基因工程技术领域,具体涉及鳜传染性脾肾坏死病毒(ISKNV)ORF093蛋白的应用。
背景技术
鳜(Siniperca
chuatsi)是我国重要的淡水鱼特色养殖品种之一,由传染性脾肾坏死病毒(Infectious
spleen and kidney necrosis virus, ISKNV)引起的鳜鱼虹彩病毒病是鳜鱼养殖的主要疫病,导致鳜死亡率接近100%,成为制约鳜养殖业发展的主要瓶颈。长期以来,对于鳜病毒病的防治一直没有有效的药物,而且抗生素、化药等防治疾病弊端众多,如病原耐药性、环境污染、食品安全问题等。因此作为符合环境友好和可持续发展战略的病害控制措施,疫苗、抗血清等生物制剂正成为国际现代水产养殖业的标准生产规范和研究开发的前沿热点领域。因此,研制与发展鳜传染性脾肾坏死病毒病疫苗及治疗制剂对防治鳜鱼虹彩病毒病具有战略意义,寻找新的疫苗候选抗原及抗病毒血清是当今鳜鱼虹彩病毒病研究的重点之一。
传染性脾肾坏死病毒(ISKNV)是虹彩病毒科肿大细胞属的代表种,为细胞质内寄生的具囊膜二十面体病毒,直径为150nm,含有双链DNA,基因组由111,362个碱基组成,包括125个预测开放读码框ORF(open
reading frames),鳜鱼是其主要感染宿主。目前控制病毒性疾病主要有两种手段:接种疫苗和使用抗病毒药物。在鳜虹彩病毒病疫苗研究方面,潘厚军等采用灭活组织浆疫苗对其进行防治,在室内和田间实验效果较好,但是由于疫苗材料来源于病鳜内脏组织,受季节和数量上的限制,推广应用有一定的困难。由于基因工程疫苗不受上述条件的限制,成为研制鳜ISKNV疫苗的一个理想的方法。2004年,张敏等进行了ISKNV主衣壳蛋白(Major capsid
protein, MCP) 的原核表达,采用免疫印记的方法初步确定了重组MCP蛋白与ISKNV MCP蛋白有相同的抗原特性,为ISKNV重组亚单位疫苗的研制提供了思路。2009年,付小哲等对重组MCP蛋白的免疫原性进行了初步研究,发现重组MCP蛋白有较好的免疫原性,可以激发鳜特异性免疫及非特异性免疫应答。在其他虹彩病毒病疫苗研制方面,日本的研究人员研制出抗真鲷虹彩病毒(RSIV)细胞灭活疫苗,免疫保护率在75%以上,是亚洲地区唯一成功进行商业化生产和应用鱼类病毒性疾病的疫苗。日本研究人员还对RSIV核酸疫苗(ORF380R,ORF 569R)进行了研究,结果显示重组核酸疫苗能够产生45~60%左右的免疫保护。Park等根据ORF055构建了条石鲷虹彩病毒(RBIV)核酸疫苗,结果显示免疫真鲷血清在BF-2细胞上对病毒具有一定的中和作用,但尚无免疫保护数据。在抗血清等抗病毒药物方面尚无相关研究。
到目前为止,还没有出现以ISKNV
ORF093基因作为疫苗前体及其抗血清制剂的研究报道。
发明内容
本发明提供了鳜传染性脾肾坏死病毒(ISKNV)ORF093蛋白在制备预防鳜传染性脾肾坏死病毒病疫苗及药物中的应用。
本发明所采用的技术方案如下:
鳜传染性脾肾坏死病毒(ISKNV)ORF093蛋白在制备预防鳜传染性脾肾坏死病毒病疫苗或药物中的应用。
优选的,所述(ISKNV)ORF093蛋白的氨基酸序列如SEQ ID NO:2所示。
本发明具有以下有益效果:
鳜ISKNV ORF093蛋白对鳜虹彩病毒病有较好的免疫预防作用,由ORF093重组蛋白制备的抗血清对鳜虹彩病毒病也有较好的中和效果。制备的ORF093重组核酸疫苗免疫鳜鱼30天后,保护率超过45%,由ORF093重组蛋白制备的兔抗血清对ISKNV也有较强的中和作用,中和液注射鳜鱼28天后,相对存活率超过56%。因此,鳜ISKNV ORF093蛋白可以开发成为抗鳜鱼传染性脾肾坏死病毒病新疫苗或新药物。
附图说明
图1是ISKNV ORF093基因的PCR扩增图,其中M为maker,1为ISKNV ORF093基因;
图2是SDS-PAGE分析ISKNV ORF093重组融合蛋白的表达图,其中1为蛋白marker,2为pET32a(+)空载,3为诱导表达上清,4为诱导表达前菌体,5、6为诱导表达后菌体总蛋白;
图3是SDS-PAGE分析ISKNV ORF093重组融合蛋白的纯化图,其中1为蛋白marker,2为 pET32a(+)空载,3为纯化后的重组蛋白,4为表达重组蛋白包涵体;
图4是重组质粒pET32a-093表达产物的western- bloting分析图,其中1为pET32a(+)空载,2为ORF093重组蛋白,3为预染蛋白marker;
图5是免疫斑点检测ISKNV图,其中1为鳜脑细胞,2为细胞培养的ISKNV。
具体实施方式
以下结合实施例对本发明作进一步的说明,但并不局限于此。下述实施例中所用的实验材料,如无特殊说明,均为自常规生化试剂公司购买得到。下述实施例中的%,如无特殊说明,均为质量百分含量。
实施例1
1 鳜ISKNV
ORF093重组蛋白在大肠杆菌中的原核表达
1.1 根据GenBank中传染性脾肾坏死病毒(ISKNV)[NC_003494] ORF093序列(SEQ ID NO:1)设计引物,并引入酶切位点(以下划线标注)。引物序列如下:
P1:【5`- CGGAATTCATGAATAAAACGC -3'】(SEQ ID NO:3),引入EcoRⅠ酶切位点;
P2:【5'- CGGAAGCTTTTAAACATGGCGTC -3'】(SEQ ID NO:4),引入HindⅢ酶切位点。
1.2 以本实验室自保存的鳜ISKNV基因组为模板进行PCR扩增,25μL PCR反应体系包含:10×buffer(含Mg2+)2.5μL,4×dNTP(10mmol/L)0.5μL,上下游引物(20μmol/L)各0.5μL,Taq DNA聚合酶(5U/μL)0.3μL,DNA 1.0μL,无菌双蒸水补足。PCR反应条件:94℃预变性4min;94℃变性45S,50℃复性45S,72℃延伸30S,30个循环;72℃延伸10min。PCR产物经1%琼脂糖凝胶电泳检测后,结果显示,在900bp左右出现亮带,片段大小与预期927bp基本相符(见图1),将目的产物进行胶回收纯化,送至测序公司测序,序列见SEQ ID NO:1。
1.3 将纯化后的ISKNV ORF093 PCR产物及提取的原核表达质粒pET32a(+),分别用HindⅢ和EcoRⅠ进行双酶切。pET32a(+)的酶切体系为:10×NEB Buffer 5μL,100×BSA 0.5μL,EcoRⅠ(20U/μL)1μL,HindⅢ(20U/μL)1μL,pET32a(+)15μL(7μg/μL),灭菌双蒸水补足50μL。ORF093 PCR产物酶切体系为:10×NEB Buffer
5μL,100×BSA
0.5μL,EcoRⅠ(20U/μL)1μL,HindⅢ(20U/μL)1μL,ORF09340μL(2.5μg/μL),灭菌双蒸水补足50μL。将酶切产物进行胶回收纯化。
1.4 将纯化后的PCR产物和pET32a(+)质粒16℃连接过夜,连接体系为:pET32a(+) (9ng/μL) 3.0μL,ORF093 5.0μL(7ng/μL),T4 DNA ligase
(5U/μL) 1.0μL,2×Rapid
Ligation Buffer 1.0μL。
1.5 将连接反应液5μL加入100μL DH5α感受态细胞(Takara, Japan)中,轻轻旋转离心管以混匀,置冰浴30min后,将感受态细胞置于42℃水浴热激90S,然后快速转到冰浴中冷却3min。再向每个离心管中加入900μL灭菌的LB培养基,混匀后置于37℃摇床振荡培养45min(转速200rpm/min)。吸取100μL已转化的感受态细胞涂布LB平板(含amp 50μg/mL),37℃正置培养30min后,倒置培养16h。
1.6 挑取白色菌落,接种于3mL加Amp(终浓度50μg/mL)的LB液体培养基中,37℃ 200rpm培养过夜。吸取1mL菌液转入1.5mL离心管中,送至测序公司测序,鉴定重组表达载体pET32a-ORF093是否正确构建,序列见SEQ ID NO:1。
1.7 吸取含有鉴定正确的pET32a-ORF093 DH5α菌液30μL加到3 mL含有Amp (终浓度50μg/mL)的LB液体培养基中,37℃、200rpm培养过夜。采用质粒提取试剂盒(OMEGA, USA)提取重组质粒pET32a-ORF093。取2μL重组质粒加入100μL BL21(DE3)感受态细胞(Takara, Japan)中进行转化,后续实验方法见步骤1.5。
1.8 挑取白色菌落,接种于3ml加Amp(终浓度50μg/ mL)LB培养基中,37℃震荡过夜,按1%的接种量再次接种于含有Amp培养基中继续培养至OD值为0.6,加入IPTG(终浓度为1mmol/L),37℃诱导表达4h。
1.9 收集菌体进行SDS-PAGE分析。配制15%的分离胶和5%的浓缩胶。吸取20μl菌液,加入等体积2×SDS-PAGE上样缓冲液,混匀后100℃水浴5min,吸取20μl样品加入点样孔中,120V电泳,待溴酚蓝指示剂达到底部边缘时停止电泳,将凝胶置于新配的考马斯亮蓝染色液中,染色1h,回收考马斯亮蓝染色液,加入脱色液室温下摇动脱色,直至背景颜色完全脱去。结果显示在约36KD处有一条特异性表达带,与预期大小相符(见图2),其氨基酸序列见SEQ ID NO:2。
1.10 融合蛋白按照Bugbuster His Bind Purfification Kit(NOVAGEN,Canada)说明书进行纯化。
1.11 将纯化好的蛋白溶液装入透析袋,4℃依次用透析液1、2、3、4、5进行透析,透析时间依次为2h、2h、3h、3h、15h(过夜)。再将透析好的蛋白溶液用PEG20000进行浓缩。吸出透析好的样品溶液,12000rpm离心10min ,取10μl上清进行SDS-PAGE分析(见图3),方法见步骤1.9。
透析液1:50 mM Tris-Cl (pH8.5), 4 mM Urea ,5mM EDTA,
5mMß-巯基乙醇,20% 甘油 ;
透析液2:50 mM Tris-Cl (pH8.5), 2 mM Urea ,2.5mM EDTA,
2.5mMß-巯基乙醇,20% 甘油;
透析液3:50 mM Tris-Cl (pH8.5),1 mM Urea,1mM EDTA,
1mMß-巯基乙醇,20% 甘油;
透析液4:50 mM Tris-Cl (pH8.5),0.5 mM Urea,5mM EDTA,
0.5mMß-巯基乙醇,20% 甘油;
透析液5:50 mM Tris-Cl (pH8.5),20% 甘油。
2
抗重组
ORF093
融合蛋白多克隆抗体的制备
2.1 将复性后的ORF093重组蛋白浓度调整为2mg/mL,与等体积的弗氏完全佐剂充分乳化。
2.2 取新西兰白兔2只,一只注射ORF093重组蛋白,一只注射PBS(pH7.4)。注射前,从耳静脉取1ml血制备血清,作为对照。
2.3 首次免疫采用皮下多点注射方式进行,每只注射2ml。免疫15天后进行加强免疫,加强免疫时采用弗氏不完全佐剂乳化,免疫剂量为初次免疫的2/3。以后每隔7天加强免疫一次,免疫剂量为初次免疫的2/3。每次加强免疫前均由耳静脉取血1ml,ELISA检测抗体效价。
2.4 待效价达到所需效价时,割断兔颈动脉放血。50mL离心管收集全血,室温静置1h,待其凝固后,放置4℃冰箱过夜。4℃下5000rmp离心10min,取上清即血清。在血清中加入0.05%叠氮钠,小管分装后-20℃保存。
3
免疫印记分析抗重组
ORF093
融合蛋白多克隆抗体
3.1 将纯化后的重组ORF093融合蛋白样品进行SDS-PAGE电泳,方法见步骤1.9。
3.2 电泳完毕后,将凝胶上分离的蛋白转移到硝酸纤维素滤膜(NC膜)上,在80mA的电流下转移4h,丽春红染色观察转移情况。
3.3 用含5%的脱脂奶粉的封闭液封闭无关蛋白的潜在结合位点,室温摇床孵育1h。
3.4 弃封闭液,立即加入抗重组ORF093 融合蛋白多克隆抗体和新的封闭液(1:100),4℃孵育1h。
3.5 转移掉封闭液,用PBS漂洗3次,10min/次。最后用TBS漂洗1次,10min。
3.6 取2μL辣根酶标记的山羊抗兔IgG(H+L)稀释于10mL溶解液中(5%脱脂奶粉,50mM Tris-Cl,pH7.5,150mM NaCl)(1:5000),将膜浸泡于此液中,排除袋里气泡,然后密闭袋口,摇床上轻摇,37℃1h。
3.7 去掉辣根过氧化物酶溶液,TBS漂洗3次,10min/次。漂洗后的膜移入干净培养皿,按膜面积加入0.1mL/cm2的底物溶液(DAB)与H2O2混合液(10mL底物溶液加入10μL 30%H2O2液,混匀后立即使用)。
3.8 室温轻摇,仔细观察蛋白带的生色反应,一旦蛋白带的颜色深度达到要求(约2-3min),即用水稍为漂洗,将滤膜转移到装PBS的培养皿中,终止反应。结果显示,抗血清能与重组蛋白发生反应,并显示出一条相应大小的蛋白条带(见图4)。
4.
免疫斑点分析
抗重组
ORF093
融合蛋白多克隆抗体
4.1 将鳜脑细胞传瓶至25cm2的细胞培养瓶,待细胞形成汇合的单层后,吸出培养瓶中的培养基,然后加入约1ml的ISKNV病毒滤液,27℃约1h 进行病毒吸附。吸出感染上清,加入细胞维持液(L-15添加5%的FBS),置27℃细胞培养箱培养5天。
4.2 将ISKNV的细胞培养物,反复冻溶3次后,40000rpm/min离心,沉淀用TE缓冲液溶解,未感染的鳜脑细胞也经同样处理。
4.3 将5μL溶解的沉淀点在硝酸纤维素滤膜上,设鳜脑细胞做阴性对照。60℃烘干1h,用含5%的脱脂奶粉的封闭液封闭,室温摇床孵育1h。以后操作均与免疫印迹分析相同,方法见步骤3.5~3.8。结果显示,ISKNV的细胞样品处有明显的斑点出现,而鳜脑细胞对照则没有斑点(见图5),说明重组ORF093抗血清可以和ISKNV反应,重组ORF093有与ISKNV ORF093相似的抗原特性。
5.
鳜
ISKNV
与抗重组
ORF093
融合蛋白多克隆抗体
中和试验
5.1 实验鳜鱼(购自广东省佛山市荷塘镇三根养殖场),体质量40-50g,在充气及流水养殖池内暂养2周。从中随机挑取20尾,经镜检观察寄生虫、肝脏分离细菌、PCR检测ISKNV全部阴性,确认健康后用于实验。实验期间水温27~31℃,每天投喂饵料鱼(鲮鱼),攻毒后改为每隔3天投喂一次饵料鱼。
5.2 取具有典型鳜病毒病症状的鳜鱼脾和头肾,经PCR检测为ISKNV阳性后,以1:10质量体积比加PBS冰浴匀浆,4℃ 4 000r/min离心30min,取上清经0.22 μm微孔滤膜过滤除菌,加入青霉素和链霉素至1000
UI/ml,4℃冰箱中保存。取病毒滤液接种于胰蛋白胨琼脂培养基上,培养温度为30℃,48h后,观察培养基上无细菌生长,此病毒滤液用于中和试验。
5.3 将实验鳜鱼随机分为3个实验组,分别为093组、阳性对照组、阴性对照组,每组30尾,每个组设一个平行对照组。将制备好的兔抗重组ORF093融合蛋白血清与病毒滤液按1:1比例混合,4℃放置过夜(12小时左右),次日腹腔注射093组鱼体;阳性对照组腹腔注射病毒滤液;阴性对照组腹腔注射PBS(pH7.4)。各组的注射体积均为200μL/尾。观察28天,每天记录发病情况。结果显示(见表1),28天后,093组、阳性对照组、阴性对照组各组的平均累积死亡率分别为43.3%、100%、0,093组的相对保护率为56.7%,说明制备的抗重组ORF093 融合蛋白多克隆抗体对ISKNV具有较好的中和效果,可以用来制备防治鳜虹彩病毒病的药物制剂。
实施例
2
1. ISKNV ORF093
真核表达载体的构建
1.1 根据GenBank中传染性脾肾坏死病毒(ISKNV)[NC_003494] ORF093序列(SEQ ID NO:1)设计引物,并引入酶切位点(以下划线标注)。引物序列如下:
P3:【5’-ATGGTACCA
TGGTTTCGAGTGCACTGCT-3’】(SEQ
ID NO:5),引入KpnⅠ酶切位点;
P4:【5’-ATGAATTCTTAGGCCATAATGCCGCG
-3’】(SEQ ID NO:6),引入EcoRⅠ酶切位点。
1.2 以pET32a- ORF 093质粒为模板进行PCR扩增,25μL PCR反应体系包含:10×buffer(含Mg2+)2.5μL,4×dNTP(10mmol/L)0.5μL,上下游引物(20μmol/L)各0.5μL,Taq DNA聚合酶(5U/μL)0.3μL,DNA 1.0μL,无菌双蒸水补足。PCR反应条件:94℃预变性4min;94℃变性45S,68℃复性45S,72℃延伸30S,30个循环;72℃延伸10min。PCR产物经1%琼脂糖凝胶电泳检测后,结果显示,在900bp左右出现亮带,片段大小与预期927bp基本相符(见图1),将目的产物进行胶回收纯化,送至测序公司测序。序列见SEQ ID NO:1。
1.3 将纯化后的ISKNV ORF093 PCR产物及提取的真核表达质粒pcDNA3.1+,分别用KpnⅠ和EcoRⅠ进行双酶切。pcDNA3.1+的酶切体系为:10×NEB Buffer 5μL,100×BSA 0.5μL,EcoRⅠ(20U/μL)1μL,HindⅢ(20U/μL)1μL,pcDNA3.1+ 20μL(5μg/μL),灭菌双蒸水补足50μL。ORF093PCR产物的酶切体系为:10×NEB Buffer 5μL,100×BSA 0.5μL,EcoRⅠ(20U/μL)1μL,HindⅢ(20U/μL)1μL,ORF093 10μL(10μg/μL),灭菌双蒸水补足50μL。将酶切产物进行胶回收纯化。
1.4 将纯化后的PCR产物和pcDNA3.1+质粒16℃连接过夜,连接体系为:pcDNA3.1+ 5μL(10ng/μL),ORF093 8μL(10ng/μL),T4
DNA ligase (5U/μL) 2μL,2×Rapid Ligation Buffer 2.0μL。
1.5 将连接反应液10μL加入100μL DH5α感受态细胞(Takara, Japan)中,轻轻旋转离心管以混匀,置冰浴30min后,将感受态细胞置于42℃水浴热激90S,然后快速转到冰浴中冷却3min。再向每个离心管中加入900μL灭菌的LB培养基,混匀后置于37℃摇床振荡培养45min(转速200rpm/min)。吸取100μL已转化的感受态细胞涂布LB平板(含amp 50μg/mL),37℃正置培养30min后,倒置培养16h。
1.6 挑取白色菌落,接种于3mL加Amp(终浓度50μg/mL)的LB液体培养基中,37℃ 200rpm培养过夜。吸取1mL菌液转入1.5mL离心管中,送至测序公司测序,鉴定重组表达载体pcDNA093是否正确构建。序列见SEQ ID NO:1。
2
. ISKNV ORF093
核酸疫苗
免疫保护试验
2.1 实验鱼的准备见实施例1步骤5.1。
2.2 将实验鳜鱼随机分为2个实验组,分别为093组、对照组,每组30尾。其中093组背肌注射pcDNA093(20μg/尾),对照组背肌注射Tris-Cl(50mmol/L,pH8.5)。各组的注射体积均为50μL/尾。
2.3 病毒液制备方法见实施例1步骤5.2。
2.4 免疫后30天,背肌注射病毒液100μL,连续观察15d,每天早晚观察记录各组鱼的死亡情况。取死亡鱼的脾、肾进行ISKNV的PCR检测,对肝、脾、肾、脑进行细菌分离,以确定死因,并计算相对免疫保护率(Relative percentage survival,RPS)。结果显示(见表2),093组的相对保护率为45.3%,说明ORF093蛋白有较好的免疫原性,可以作为制备鳜虹彩病毒病疫苗的候选抗原。
<110> 中国水产科学研究院珠江水产研究所
<120> 鳜传染性脾肾坏死病毒(ISKNV)ORF093蛋白的应用
<130>
<160> 6
<170> PatentIn version 3.5
<210> 1
<211> 927
<212> DNA
<213> 传染性脾肾坏死病毒(Infectious spleen and kidney necrosis virus, ISKNV)
<400> 1
atgatttcga gtgcactgct
gacgaccaag acgagcttca ggcacgtcga gacccccgcg 60
acgtacctgc caaagataca
ccgcggacct cgaccgcagc catcgagtac actgaggcca
120
caacgagtgc atgtcgatat
ggtggcagaa gctaagagag tggcggctgt ggaccatgtc
180
gcactccaac accccaacta
cgccaaggtg tctgtgcaca cagaagccag gccgactgtg
240
acactggacg tgctggccac
tgtggacatt gagctgcctg gacgtaacgg catcctcctt
300
ggtgatcgcg ctacagtaca
cggcggcatt cccgtgacat cgcatggaaa taaacccttt
360
acggatggcg tcaagtttgc
cgacattgga caccagctca ctgcggggca tgaggccagt
420
aacaaacaac tattctctag
gcatgctatg cccatgggac cgcccgctgt gccggagagt
480
gtcatgccag gtagccgcat
tacccccgtc ggcaccggcg ttgtgtacac tgctccagac
540
ggtgtgcgtc gagcctccca
ccgatcttcg ctgggcgcgg ccaagtactt gtctgacaat
600
gccgttgcga cgggccacag
tgcacccggc gtggtgagcc gcaacacggt gaagaggccg
660
gaccatgtca agacgtctat
agccatgata gggcggacaa acacgtctag ggtagcggca
720
ccatcagaca gcaatcgcat
cggacaagct acacagccgc atgtacgggc gtatacacag
780
caaccaacac gggccgacgc
gcacaccatg cccacaaccg gctcaatgca cactgataca
840
cagaggccgg tggtcatctc
aggcggcatg acgaccgttc ccatggccca tggacagtcc
900
ttcgagggac gcggcattat
ggcctaa
927
<210> 2
<211> 308
<212> PRT
<213> 传染性脾肾坏死病毒(Infectious spleen and kidney necrosis virus, ISKNV)
<400> 2
Met Ile Ser Ser Ala Leu
Leu Thr Thr Lys Thr Ser Phe Arg His Val
1 5 10 15
Glu Thr Pro Ala Thr Tyr
Leu Pro Lys Ile His Arg Gly Pro Arg Pro
20 25 30
Gln Pro Ser Ser Thr Leu
Arg Pro Gln Arg Val His Val Asp Met Val
35 40 45
Ala Glu Ala Lys Arg Val
Ala Ala Val Asp His Val Ala Leu Gln His
50 55 60
Pro Asn Tyr Ala Lys Val
Ser Val His Thr Glu Ala Arg Pro Thr Val
65 70 75 80
Thr Leu Asp Val Leu Ala
Thr Val Asp Ile Glu Leu Pro Gly Arg Asn
85 90 95
Gly Ile Leu Leu Gly Asp
Arg Ala Thr Val His Gly Gly Ile Pro Val
100 105 110
Thr Ser His Gly Asn Lys
Pro Phe Thr Asp Gly Val Lys Phe Ala Asp
115 120 125
Ile Gly His Gln Leu Thr
Ala Gly His Glu Ala Ser Asn Lys Gln Leu
130 135 140
Phe Ser Arg His Ala Met
Pro Met Gly Pro Pro Ala Val Pro Glu Ser
145 150 155 160
Val Met Pro Gly Ser Arg
Ile Thr Pro Val Gly Thr Gly Val Val Tyr
165 170 175
Thr Ala Pro Asp Gly Val
Arg Arg Ala Ser His Arg Ser Ser Leu Gly
180 185 190
Ala Ala Lys Tyr Leu Ser
Asp Asn Ala Val Ala Thr Gly His Ser Ala
195 200 205
Pro Gly Val Val Ser Arg
Asn Thr Val Lys Arg Pro Asp His Val Lys
210 215 220
Thr Ser Ile Ala Met Ile
Gly Arg Thr Asn Thr Ser Arg Val Ala Ala
225 230 235 240
Pro Ser Asp Ser Asn Arg
Ile Gly Gln Ala Thr Gln Pro His Val Arg
245 250 255
Ala Tyr Thr Gln Gln Pro
Thr Arg Ala Asp Ala His Thr Met Pro Thr
260 265 270
Thr Gly Ser Met His Thr
Asp Thr Gln Arg Pro Val Val Ile Ser Gly
275 280 285
Gly Met Thr Thr Val Pro
Met Ala His Gly Gln Ser Phe Glu Gly Arg
290 295 300
Gly Ile Met Ala
305
<210> 3
<211> 21
<212> DNA
<213> 人工引物
<400> 3
cggaattcat gaataaaacg
c 21
<210> 4
<211> 23
<212> DNA
<213> 人工引物
<400> 4
cggaagcttt taaacatggc
gtc
23
<210> 5
<211> 28
<212> DNA
<213> 人工引物
<400> 5
atggtaccat ggtttcgagt
gcactgct 28
<210> 6
<211> 26
<212> DNA
<213> 人工引物
<400> 6
atgaattctt aggccataat
gccgcg 26
Claims (1)
1.鳜传染性脾肾坏死病毒
ORF093蛋白在制备预防鳜传染性脾肾坏死病毒病疫苗或药物中的应用,所述鳜传染性脾肾坏死病毒
ORF093蛋白的氨基酸序列如SEQ ID NO:2所示。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110191339 CN102240399B (zh) | 2011-07-09 | 2011-07-09 | 鳜传染性脾肾坏死病毒(isknv)orf093蛋白的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110191339 CN102240399B (zh) | 2011-07-09 | 2011-07-09 | 鳜传染性脾肾坏死病毒(isknv)orf093蛋白的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102240399A CN102240399A (zh) | 2011-11-16 |
CN102240399B true CN102240399B (zh) | 2013-06-19 |
Family
ID=44958757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110191339 Expired - Fee Related CN102240399B (zh) | 2011-07-09 | 2011-07-09 | 鳜传染性脾肾坏死病毒(isknv)orf093蛋白的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102240399B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103952495B (zh) * | 2014-03-21 | 2016-01-06 | 华中农业大学 | 一种鳜鱼传染性脾肾坏死病毒的lamp检测方法 |
CN104096240A (zh) * | 2014-06-20 | 2014-10-15 | 中国水产科学研究院珠江水产研究所 | 一种抗传染性脾肾坏死病毒的dna疫苗 |
CN106310295A (zh) * | 2016-10-26 | 2017-01-11 | 武汉市农业科学技术研究院水产科学研究所 | 一种dna疫苗浸泡免疫预防鳜鱼isknv的方法 |
CN114106112B (zh) * | 2021-11-30 | 2023-07-07 | 西北农林科技大学 | 截短表达的鳜传染性脾肾坏死病毒主衣壳蛋白及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1186459C (zh) * | 2003-05-06 | 2005-01-26 | 中山大学 | 鳜鱼传染性脾肾坏死病毒基因诊断试剂盒及检测方法 |
-
2011
- 2011-07-09 CN CN 201110191339 patent/CN102240399B/zh not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
Cheng-Yin Shi,et al..Complete genome sequence of a Megalocytivirus (family Iridoviridae) associated with turbot mortality in China.《Virology Journal》.2010,第7卷(第159期),1-9. * |
Christopher Marlowe A. Caipang,et al..Genetic vaccines protect red seabream, Pagrus major, upon challenge with red seabream iridovirus (RSIV).《Fish & Shellfish Immunology》.2005,第21卷130-138. |
Christopher Marlowe A. Caipang,et al..Genetic vaccines protect red seabream, Pagrus major, upon challenge with red seabream iridovirus (RSIV).《Fish & * |
Shellfish Immunology》.2005,第21卷130-138. * |
Also Published As
Publication number | Publication date |
---|---|
CN102240399A (zh) | 2011-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101788563B (zh) | 梅花鹿γ-干扰素双抗体夹心ELISA检测方法及试剂盒与应用 | |
CN103694323A (zh) | 金黄色葡萄球菌MntC重组蛋白及其制备方法和应用 | |
CN105462936B (zh) | 一种猪流行性腹泻病毒my01株及其应用 | |
CN101724605B (zh) | 抗***病毒的单克隆抗体及其识别的抗原表位和应用 | |
CN102240399B (zh) | 鳜传染性脾肾坏死病毒(isknv)orf093蛋白的应用 | |
CN108823218A (zh) | 鸡传染性法氏囊病病毒vp2基因、其表达产物、其亚单位疫苗及应用 | |
CN103191421B (zh) | 一株血清5型副猪嗜血杆菌疫苗株的应用 | |
CN103694321B (zh) | 金黄色葡萄球菌mSEB突变体及其制备方法和应用 | |
CN103421832B (zh) | 包含氟苯尼考耐药基因蛋白的卵黄抗体及制备与应用 | |
CN107236039A (zh) | 重组Wzt蛋白兔血清多克隆抗体及其制备方法 | |
CN107510841A (zh) | 源头阻断包虫病病原细粒棘球绦虫传播的疫苗 | |
CN104974249A (zh) | 鸭疫里默氏菌OmpA/MotB截短重组蛋白、其抗体及制备方法和应用 | |
CN102993308B (zh) | 耐甲氧西林金黄色葡萄球菌(mrsa)疫苗重组蛋白抗原hi2及制备方法和应用 | |
CN101293098A (zh) | 一种重组牛o型***病毒融合蛋白疫苗 | |
CN103725697B (zh) | 化学合成的金黄色葡萄球菌的表面蛋白FnBPA基因片段及其表达、应用 | |
CN102604993B (zh) | 免疫佐剂与幽门螺杆菌抗原融合蛋白口服疫苗及其制备方法 | |
CN103194412B (zh) | 一株血清5型副猪嗜血杆菌疫苗株 | |
CN104974231A (zh) | 一种新的猪繁殖与呼吸综合征病毒变异株gp5重组蛋白及其制备方法及应用 | |
CN102580074A (zh) | 鸭疫里氏杆菌和大肠杆菌外膜蛋白二联疫苗及其制备方法 | |
CN106008678A (zh) | 抑制产气荚膜梭菌感染的融合蛋白及其相关生物材料与应用 | |
CN107982527A (zh) | 外膜蛋白vp1243在防治弧菌感染中的应用 | |
CN102977214B (zh) | 用于耐甲氧西林金黄色葡萄球菌(mrsa)疫苗的重组蛋白hf2及制备方法和应用 | |
TW201236693A (en) | Method of inducing antibody in birds by the OmpA of Riemerella anatipestifer and the Riemerella anatipestifer vaccine | |
CN103483430B (zh) | 蛋白a1g_07050在抗立氏立克次体的免疫保护中的应用 | |
CN110526959A (zh) | 一种***病毒抗原、表达***病毒抗原的基因及其重组载体和重组乳酸乳球菌 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130619 |